QVT Financial’s Biogen BIIB Stock Holding History

QVT Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11,760	Closed	-$3.21M	–	76
2017 Q1	$3.21M	Hold	11,760	–	–	0.1%	68
2016 Q4	$3.33M	Buy	+11,760	New	+$3.49M	0.1%	75

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QVT Financial's BIIB Position: Q2 2017 in Review

QVT Financial sold out of Biogen (BIIB) in Q2 2017, closing a stake of 11,760 shares — an estimated $3.21M sold.

QVT Financial first reported a position in BIIB in Q4 2016 and held it in 2 quarters. The position peaked at $3.33M in Q4 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

QVT Financial reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
QVT Financial sold 11,760 Biogen shares in Q2 2017, an estimated $3.21M.
QVT Financial first reported a position in Biogen in Q4 2016 and held it in 2 quarters.
QVT Financial's Biogen position peaked at $3.33M in Q4 2016.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on QVT Financial's 13F filing for Q2 2017, filed 14 Aug 2017.